Company profile: EnPlusOne Biosciences
1.1 - Company Overview
Company description
- Provider of an ezRNA platform enabling incorporation of standard and non-standard nucleobases and their modifications, supporting installation of standard and phosphorothioated backbones, and integrating 2' modifications essential for siRNA therapeutics and novel variants. Offers 3' modifications including linkers and chain terminators for emerging RNA therapeutics.
Products and services
- EzRNA™ Platform: Modular platform that incorporates standard and non-standard nucleobases and applies nucleobase-specific modifications to architect complex RNA sequences for emerging therapeutics
- 2’- Modifications: Custom-engineered sugar-ring changes enabling incorporation of all standard 2’ modifications essential for siRNA therapeutics, plus novel 2’ modifications through the ezRNA™ platform
- Standard and Phosphorothioated Backbones: Chemistry-grade backbone installation supporting canonical phosphate backbones and phosphorothioate linkages for RNA constructs, integrated within the ezRNA™ platform workflow
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to EnPlusOne Biosciences
GenVec
HQ: United States
Website
- Description: Provider of differentiated, proprietary biopharmaceutical technologies for the creation of therapeutics and vaccines, developing and commercializing product candidates through collaborations with leading companies and organizations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenVec company profile →
Genenta
HQ: Italy
Website
- Description: Provider of gene transfer therapy for cancer, including Temferon, a lentiviral hematopoietic stem progenitor cell immunotherapy enabling controlled, targeted interferon-α expression within tumors to generate immune responses to TEMs-positive cancers. Offers a proprietary cell-based platform using hematopoietic stem cells to deliver therapeutic payloads in the tumor microenvironment for durable, safe treatment of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genenta company profile →
Prevail Therapeutics
HQ: United States
Website
- Description: Provider of novel AAV9-based gene therapies for neurodegenerative diseases. Offerings include PR001, delivering a healthy GBA1 gene to correct lysosomal dysfunction in Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, and PR006, delivering a healthy GRN gene to raise progranulin for frontotemporal dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prevail Therapeutics company profile →
Phio Pharmaceuticals
HQ: United States
Website
- Description: Provider of RNAi immuno-oncology therapies leveraging the INTASYL self-delivering RNAi platform to create siRNA compounds that silence gene targets. Pipeline includes PH-762 (intratumoral PD-1 silencing for cSCC, melanoma, Merkel cell carcinoma), PH-894 (intratumoral BRD4 silencing for advanced melanoma and other cancers), and PH-762 + adoptive cell therapy with double positive CD8 Tils (IV for stage IV melanoma and solid tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phio Pharmaceuticals company profile →
American Gene Technologies
HQ: United States
Website
- Description: Provider of gene therapy solutions for infectious diseases, cancers, and inherited disorders. Offerings include AGT103-T, an autologous genetically modified cell product to repair HIV-related immune damage and enable natural control of replication; a PKU gene therapy expected to enter trials in 2025; an immuno-oncology program activating γδ T cells to destroy solid tumors; and a proprietary gene-delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full American Gene Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for EnPlusOne Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to EnPlusOne Biosciences
2.2 - Growth funds investing in similar companies to EnPlusOne Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for EnPlusOne Biosciences
4.2 - Public trading comparable groups for EnPlusOne Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →